Skip to main content
Advertisement
Advertisement
XERS
XERS logo
Xeris Biopharma Holdings, Inc. Common Stock
16.97
USD
Sponsored
+0.35
+2.11%
Nov 20, 15:59 UTC -5
Closed
exchange

After-Market

16.97

0.00
-0.01%

Xeris Biopharma Holdings, Inc. Common Stock (XERS) Earnings

XERS Earnings Reports

Positive Surprise Ratio

XERS beat 19 of 34 last estimates.

56%

Next Report

Date of Next Report
Mar 01, 2027
Estimate for Q4 26 (Revenue/ EPS)
$120.99M
/
$0.04
Implied change from Q3 26 (Revenue/ EPS)
+12.84%
/
-33.33%
Implied change from Q4 25 (Revenue/ EPS)
+41.00%
/
-33.33%

Xeris Biopharma Holdings, Inc. Common Stock earnings per share and revenue

On Nov 05, 2026, XERS reported earnings of 0.06 USD per share (EPS) for Q3 26, beating the estimate of 0.02 USD, resulting in a 144.90% surprise. Revenue reached 107.22 million, compared to an expected 103.55 million, with a 3.55% difference. The market reacted with a +25.05% price change (close before vs. close after earnings).
Looking ahead to Q4 26, -- analysts forecast an EPS of 0.04 USD, with revenue projected to reach 120.99 million USD, implying an decrease of -33.33% EPS, and increase of 12.84% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Apnimed, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.62
Actual
-$0.99
Surprise
-59.11%
logo
Larimar Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.35
Actual
-$0.28
Surprise
+17.38%
logo
Lexeo Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.33
Actual
-$0.43
Surprise
-28.17%
logo
Galectin Therapeutics Inc.
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.05
Actual
-$0.04
Surprise
+21.57%
logo
NRX Pharmaceuticals, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.21
Actual
-$0.05
Surprise
+76.94%
logo
Unicycive Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.32
Actual
-$0.25
Surprise
+21.88%
logo
Actinium Pharmaceuticals, Inc
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.24
Actual
-$0.19
Surprise
+23.45%
logo
Marker Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.11
Actual
-$0.10
Surprise
+15.97%
logo
Scienture Holdings, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$1.60
Actual
-$3.76
Surprise
-134.79%
logo
60 Degrees Pharmaceuticals, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.74
Actual
-$0.75
Surprise
-0.73%
FAQ
For Q3 2026, Xeris Biopharma Holdings, Inc. Common Stock reported EPS of $0.06, beating estimates by 144.9%, and revenue of $107.22M, 3.55% above expectations.
The stock price moved up 25.05%, changed from $10.46 before the earnings release to $13.08 the day after.
The next earning report is scheduled for Mar 01, 2027.
Based on -- analysts, Xeris Biopharma Holdings, Inc. Common Stock is expected to report EPS of $0.04 and revenue of $120.99M for Q4 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement